Literature DB >> 18836779

Contralateral risk-reducing mastectomy in young breast cancer patients with and without genetic cancer risk assessment.

Phuong L Mai1, Veronica I Lagos, Melanie R Palomares, Jeffrey N Weitzel.   

Abstract

BACKGROUND: Decisions regarding contralateral risk-reducing mastectomy (CRRM) among women diagnosed with unilateral breast cancer can potentially be influenced by age at diagnosis and other factors. In this study, we examined the use of CRRM before versus after genetic cancer risk assessment (GCRA) in women diagnosed with breast cancer before age 50.
METHODS: We conducted a retrospective analysis of women with invasive breast cancer diagnosed before age 50 who were seen for GCRA between October 1996 and March 2005. Associations between the presence of generally accepted indications for risk-reducing surgery among women who had CRRM and the timing of GCRA were examined.
RESULTS: The cohort included 378 women, of whom 57 had CRRM pre-GCRA and 45 had CRRM post-GCRA after a median follow-up of 26 months. Women who had CRRM pre-GCRA were more likely to not have a generally accepted indication for the procedure than those who did after GCRA (odds ratio [OR] 5.3, 95% confidence interval [95% CI] 1.6-17.8, P = .007). Women diagnosed with breast cancer before BRCA genetic testing became clinically available (1997) were more likely to have had CRRM pre-GCRA than those who were diagnosed more recently (OR 2.9, 95% CI 1.6-5.2, P = .0003).
CONCLUSION: When personal and family history was carefully examined, a substantial proportion of women seen in our clinic did not have a clear indication for CRRM. Decreased use of empiric CRRM among women diagnosed after 1997 may indicate increased awareness and use of GCRA. Thus, judicious application of GCRA may help focus use of surgical risk reduction measures to the most risk-appropriate patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18836779      PMCID: PMC2993252          DOI: 10.1245/s10434-008-0160-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  42 in total

1.  Society of Surgical Oncology: position statement on prophylactic mastectomy. Approved by the Society of Surgical Oncology Executive Council, March 2007.

Authors:  Armando E Giuliano; Susan Boolbol; Amy Degnim; Henry Kuerer; A Marilyn Leitch; Monica Morrow
Journal:  Ann Surg Oncol       Date:  2007-06-28       Impact factor: 5.344

2.  Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.

Authors:  H Meijers-Heijboer; B van Geel; W L van Putten; S C Henzen-Logmans; C Seynaeve; M B Menke-Pluymers; C C Bartels; L C Verhoog; A M van den Ouweland; M F Niermeijer; C T Brekelmans; J G Klijn
Journal:  N Engl J Med       Date:  2001-07-19       Impact factor: 91.245

3.  Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer.

Authors:  E A Peralta; J D Ellenhorn; L D Wagman; A Dagis; J S Andersen; D Z Chu
Journal:  Am J Surg       Date:  2000-12       Impact factor: 2.565

Review 4.  ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes.

Authors:  José G Guillem; William C Wood; Jeffrey F Moley; Andrew Berchuck; Beth Y Karlan; David G Mutch; Robert F Gagel; Jeffrey Weitzel; Monica Morrow; Barbara L Weber; Francis Giardiello; Miguel A Rodriguez-Bigas; James Church; Stephen Gruber; Kenneth Offit
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

5.  Cancer statistics, 2008.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Taylor Murray; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2008-02-20       Impact factor: 508.702

6.  Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment.

Authors:  Todd M Tuttle; Elizabeth B Habermann; Erin H Grund; Todd J Morris; Beth A Virnig
Journal:  J Clin Oncol       Date:  2007-10-22       Impact factor: 44.544

Review 7.  Contralateral prophylactic mastectomy for patients with unilateral breast cancer.

Authors:  Todd Tuttle; Elizabeth Habermann; Anasooya Abraham; Timothy Emory; Beth Virnig
Journal:  Expert Rev Anticancer Ther       Date:  2007-08       Impact factor: 4.512

8.  Incidence and outcomes of contralateral breast cancers.

Authors:  Glenda Quan; SuEllen J Pommier; Rodney F Pommier
Journal:  Am J Surg       Date:  2008-05       Impact factor: 2.565

9.  Contralateral breast cancer risk is influenced by the age at onset in BRCA1-associated breast cancer.

Authors:  L C Verhoog; C T Brekelmans; C Seynaeve; E J Meijers-Heijboer; J G Klijn
Journal:  Br J Cancer       Date:  2000-08       Impact factor: 7.640

10.  The impact of genetic counselling on risk perception in women with a family history of breast cancer.

Authors:  D G Evans; V Blair; R Greenhalgh; P Hopwood; A Howell
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640

View more
  4 in total

1.  Development and evaluation of a decision aid for BRCA carriers with breast cancer.

Authors:  Julie O Culver; Deborah J MacDonald; Andrea A Thornton; Sharon R Sand; Marcia Grant; Deborah J Bowen; Harry Burke; Nellie Garcia; Kelly A Metcalfe; Jeffrey N Weitzel
Journal:  J Genet Couns       Date:  2011-03-03       Impact factor: 2.537

2.  Clinical interpretation of pathogenic ATM and CHEK2 variants on multigene panel tests: navigating moderate risk.

Authors:  Allison H West; Kathleen R Blazer; Jessica Stoll; Matthew Jones; Caroline M Weipert; Sarah M Nielsen; Sonia S Kupfer; Jeffrey N Weitzel; Olufunmilayo I Olopade
Journal:  Fam Cancer       Date:  2018-10       Impact factor: 2.375

3.  Impact that Timing of Genetic Mutation Diagnosis has on Surgical Decision Making and Outcome for BRCA1/BRCA2 Mutation Carriers with Breast Cancer.

Authors:  Akiko Chiba; Tanya L Hoskin; Emily J Hallberg; Jodie A Cogswell; Courtney N Heins; Fergus J Couch; Judy C Boughey
Journal:  Ann Surg Oncol       Date:  2016-06-23       Impact factor: 5.344

4.  Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON study.

Authors:  M R Wevers; M K Schmidt; E G Engelhardt; S Verhoef; M J Hooning; M Kriege; C Seynaeve; M Collée; C J van Asperen; R A E M Tollenaar; L B Koppert; A J Witkamp; E J T Rutgers; N K Aaronson; M A Rookus; M G E M Ausems
Journal:  Fam Cancer       Date:  2015-09       Impact factor: 2.375

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.